Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research

Non-small Cell Lung Cancer Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02513355
• Other study ID #: JS-ENDO-001
• Status: Recruiting
• Phase: Phase 4
• First received: July 17, 2015
• Last updated: July 31, 2015
• Start date: February 2015

Study information

• Verified date: February 2015
• Source: Nanjing NingQi Medicine Science and Technology Co., Ltd.
• Contact: Yin Qingfeng, manager
• Phone: 0086-025-85632992
• Email: y_qingfeng[@]163.com
• Is FDA regulated: No
• Health authority: China:Nanjing NingQi pharmaceutical technology co., LTD
• Study type: Interventional

Clinical Trial Summary

Research purpose:

Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination chemotherapy regimens including cisplatin two medicine first-line treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety.

Description:

1.Research purpose: Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination chemotherapy regimens including cisplatin two medicine first-line treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety.

2.1 main objectives: PFS 2.2 the secondary goal: 2.2. 1 ORR, DCR and OS 2.2. 2 the quality of life 3. The study design 3.1 research nature This is a single arm, multicenter clinical study, is expected to total 100 patients into the group.

Hierarchical factors include: the tumor staging (Ⅲ B vs Ⅳ), ECOG score (0 v 1), gender (male vs female).

3.2 research center and research Proposed by taizhou people's hospital and medical association of jiangsu province tumor chemotherapy and biological branch of the lung cancer group led by several large and medium-sized hospitals in the province of the malignant tumor treatment related department to participate, in accordance with the unified test plan of this research.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 400
• Est. primary completion date: November 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Histologic confirmation cytology or not in patients undergoing single sputum cytology in the diagnosis of patients with non-small cell lung cancer;

• according to a new IASLC2009 lung cancer TNM stages judged the preious untreated stage IIIB or IV non-small cell lung cancer (with the exception of EGFR/ALK mutations type);

• must have at least one according to the RRECIST version 1.1 standard judgment to evaluate lesions (at least 10 mm, maximum diameter on spiral CT plain CT longest diameter at least 20 mm);

• male or female, age 18 and 75 years old or less or more;

• ECOG PS 0 ~ 1 minute;

• is expected to survive period for 3 months or more,

• enough blood function: absolute neutrophil count (ANC) or 2 x 109 / L and the platelet count 100 x 109 / L or higher acuity 9 g/dL and hemoglobin;

• Liver function enough: upper limit of total bilirubin acuities were normal (ULN); AST and ALT acuities were 2.5 times the upper limit of normal (ULN); Alkaline phosphatase 5 times the upper limit of normal or less (ULN);

• enough renal function, serum creatinine or less normal limit (ULN) or calculated creatinine clearance or 60 mL/min.

• basic normal ecg, had on the body to heal wounds;

• always not received anti-tumor drug therapy, or always only for non metastatic tumor of adjuvant or neoadjuvant chemotherapy, but to study treatment has ended more than six months at the beginning;

• ever had had surgery patients, request to study treatment began to have more than 4 weeks, and the patient has recovered;

• a complete uterus of female in the group within 28 days before the study must have a negative pregnancy test results (except amenorrhea has 24 months). If the pregnancy test from the first time for more than 7 days, is the need for urine pregnancy test validation (within 7 days before the first delivery).

• prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions;

• signed informed consent.

Exclusion criteria

• pregnancy, nursing mothers, or fertility but not women using contraception;

• the existing serious acute infection, and not be controlled; Or fester sex and chronic infection, wound in delay no more;

• the original serious heart disease, including: higher risk of congestive heart failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension;

• is not easy to control nerve, mental illness or mental disorders, compliance is poor, can't cooperate with accounts and response to treatment; Primary brain tumors or CNS metastases illness did not get a control, has obvious symptoms in cranial hypertension or nerve spirit;

• with bleeding tendency;

• other researchers believe that patients should not participate in this test.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Biological:
• Endostar
Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles

Drug:
• Changchun marina
25mg/m2,d1 and d8,q21d×4
• cisplatin
80mg/m2,d1, q21d×4
• Taxol
135-175mg/m2,d1,q21d×4
• parapl
AUC=5-6,d1,q21d×4

Locations

Country	Name	City	State
China	Jiangsu Taizhou People's Hospital	Nanjing City	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing NingQi Medicine Science and Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS(progression-free survival)	PFS is refers to the patients randomly into group to the date of any objective records of patients with tumor progression or death time.	Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase	No
Secondary	ORR(Objective Response Rate)		1 weeks before treatment, Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase	No
Secondary	DCR(disease control rate)		Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase	No
Secondary	OS(overall survival)		Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase	No